JP2009527484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009527484A5 JP2009527484A5 JP2008555417A JP2008555417A JP2009527484A5 JP 2009527484 A5 JP2009527484 A5 JP 2009527484A5 JP 2008555417 A JP2008555417 A JP 2008555417A JP 2008555417 A JP2008555417 A JP 2008555417A JP 2009527484 A5 JP2009527484 A5 JP 2009527484A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- zileuton
- composition according
- single crystal
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005332 zileuton Drugs 0.000 claims description 20
- 239000013078 crystal Substances 0.000 claims description 14
- 208000028867 ischemia Diseases 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 206010069351 acute lung injury Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 150000002617 leukotrienes Chemical class 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 238000009423 ventilation Methods 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 102000003820 Lipoxygenases Human genes 0.000 claims description 2
- 108090000128 Lipoxygenases Proteins 0.000 claims description 2
- 208000000592 Nasal Polyps Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000007474 aortic aneurysm Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 238000000634 powder X-ray diffraction Methods 0.000 claims 8
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 7
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 238000012856 packing Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010000228 Abortion infected Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030136 Oesophageal achalasia Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 206010054048 Postoperative ileus Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000002359 Septic Abortion Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 208000001606 epiglottitis Diseases 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77557906P | 2006-02-21 | 2006-02-21 | |
| PCT/US2007/004488 WO2007098189A2 (en) | 2006-02-21 | 2007-02-21 | New crystal forms and pharmaceutical compositions of (+) -r-zileuton |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009527484A JP2009527484A (ja) | 2009-07-30 |
| JP2009527484A5 true JP2009527484A5 (enExample) | 2010-04-08 |
Family
ID=38437967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008555417A Pending JP2009527484A (ja) | 2006-02-21 | 2007-02-21 | （＋）−ｒ−ジロートンの新規結晶形態および医薬組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8003684B2 (enExample) |
| EP (2) | EP2001861A2 (enExample) |
| JP (1) | JP2009527484A (enExample) |
| AU (1) | AU2007217770B2 (enExample) |
| CA (1) | CA2642216A1 (enExample) |
| WO (1) | WO2007098189A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8445437B2 (en) * | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
| JP2010515682A (ja) * | 2007-01-05 | 2010-05-13 | コーナーストーン セラピューティックス インコーポレイテッド | 喘息などの５−リポキシゲナーゼ活性上昇および／またはロイコトリエン活性上昇に関連する状態における使用のためのｒ−ジロートン |
| JP5460600B2 (ja) * | 2007-09-28 | 2014-04-02 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 肥満症治療における肥満細胞安定化薬 |
| NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| PT2959899T (pt) * | 2011-08-23 | 2017-05-18 | Cornerstone Therapeutics Inc | Utilização de zileuton para o tratamento de pólipos nasais em pacientes com fibrose quística |
| KR101462474B1 (ko) * | 2013-10-30 | 2014-11-19 | 주식회사 큐리언트 | 질레우톤 크림 제형의 국소용 항염증 약학적 조성물 |
| US9855243B2 (en) | 2013-10-30 | 2018-01-02 | Qurient Co., Ltd. | Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation |
| US9802926B2 (en) * | 2014-06-20 | 2017-10-31 | Aviragen Therapeutics, Inc. | Anhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US279263A (en) * | 1883-06-12 | Eobeet t | ||
| EP0279263B1 (en) * | 1987-02-10 | 1993-08-04 | Abbott Laboratories | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds |
| CA2161777A1 (en) | 1993-05-10 | 1994-11-24 | Nancy M. Gray | Methods and compositions using optically pure (+)-zileuton |
| US5663368A (en) * | 1993-07-14 | 1997-09-02 | Smithkline Beecham Corporation | Synthesis of acid addition salts of hydroxylamines |
-
2007
- 2007-02-21 JP JP2008555417A patent/JP2009527484A/ja active Pending
- 2007-02-21 EP EP07751259A patent/EP2001861A2/en not_active Ceased
- 2007-02-21 AU AU2007217770A patent/AU2007217770B2/en not_active Ceased
- 2007-02-21 WO PCT/US2007/004488 patent/WO2007098189A2/en not_active Ceased
- 2007-02-21 CA CA002642216A patent/CA2642216A1/en not_active Abandoned
- 2007-02-21 EP EP11176982A patent/EP2409973A1/en not_active Withdrawn
- 2007-02-21 US US11/709,299 patent/US8003684B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009527484A5 (enExample) | ||
| US20250163023A1 (en) | Synthesis of omecamtiv mecarbil | |
| US10035802B2 (en) | Solid state forms of ibrutinib | |
| JP2013529647A5 (enExample) | ||
| JP2014515372A5 (enExample) | ||
| JP2019505568A5 (enExample) | ||
| JP2020512316A5 (enExample) | ||
| WO2014152270A1 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| CN106316889B (zh) | 依度沙班中间体的制备方法 | |
| HUE031416T2 (en) | Preparation of 2- (5-Bromo-4- (4-cyclopropylnaphthalen-1-hydrazine) -4H-1,2,4-triazole-3-hydrazine) acetic acid \ t | |
| JP2007514746A5 (enExample) | ||
| JP2011513485A5 (enExample) | ||
| JP6556293B2 (ja) | 純粋なニロチニブ及びその塩の調製のための方法 | |
| US10519117B2 (en) | Crystal forms of 6-bromo-3-hydroxy-2-pyrazinecarboxamide | |
| WO2016107289A1 (zh) | 制备索非布韦晶型6的方法 | |
| CN102321073A (zh) | 一种尼罗替尼的制备方法 | |
| JP2013541589A5 (enExample) | ||
| CN103951601B (zh) | 2-乙酰基-1-吡咯啉的合成方法 | |
| ES2710312T3 (es) | Un procedimiento para la preparación de montelukast sódico | |
| CN105777617A (zh) | 色瑞替尼的合成中间体及其制备方法 | |
| JP6387349B2 (ja) | 逆転写酵素阻害剤の結晶形態 | |
| JP4530287B2 (ja) | オキサセフェムの結晶 | |
| CN101896496B (zh) | 4-脱氧-4-氟-d-葡萄糖衍生物的制造方法 | |
| EP3374349A1 (en) | Process for the preparation of eltrombopag olamine | |
| WO2010074090A1 (ja) | ピリダジン－３（２ｈ）－オン化合物塩酸塩の結晶及びその製造方法 |